Incarceration dramatically elevates psychopharmacology risk while simultaneously limiting access to treatment — creating a significant public health crisis.
Incarceration and Psychopharmacology
People in prison and jail experience psychopharmacology at rates 3-5 times higher than the general population, driven by:
- Loss of freedom, autonomy, and dignity
- Exposure to violence and trauma in correctional environments
- Separation from family and support systems
- Uncertainty about the future
- Pre-existing psychopharmacology often underlying the criminal justice involvement
Reentry and Psychopharmacology
Release from incarceration is a high-risk period for psychopharmacology. The challenges of reintegration — housing, employment, relationships, stigma — can overwhelm coping resources.
Supporting Psychopharmacology in Justice-Involved Individuals
Trauma-informed, reentry-focused mental health services that address housing and basic needs alongside psychopharmacology treatment are most effective.